Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analyst consensus is “Hold”: All eight covering firms rate Theravance Biopharma shares a hold, with an average 12-month price target of $19.40 versus the reported share price of $17.05.
• Recent results missed expectations: The company reported a quarterly loss of $0.11 per share, missing the $0.07 consensus estimate, while revenue of $20.73 million came in below forecasts of $22.49 million.
• Insiders have been selling shares: Company insiders sold approximately 350,011 shares worth $6.02 million over the past 90 days, although institutional investors own a substantial 99.10% of the stock.

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned an average recommendation of "Hold" from the eight research firms that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a hold rating. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $19.40.

A number of equities research analysts have issued reports on TBPH shares. Zacks Research downgraded shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 7th. JonesTrading cut shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Monday, June 29th. HC Wainwright downgraded shares of Theravance Biopharma from a "buy" rating to a "neutral" rating and upped their price target for the stock from $15.00 to $17.00 in a report on Tuesday, July 7th. BTIG Research lowered shares of Theravance Biopharma from a "buy" rating to a "neutral" rating in a research report on Monday, June 29th. Finally, Weiss Ratings raised shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, August 17th.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $17.05 on Tuesday. The business has a fifty day moving average price of $16.96 and a two-hundred day moving average price of $16.41. The stock has a market capitalization of $885.24 million, a PE ratio of 16.88 and a beta of 0.25. Theravance Biopharma has a fifty-two week low of $13.08 and a fifty-two week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). The company had revenue of $20.73 million for the quarter, compared to analyst estimates of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. On average, equities analysts expect that Theravance Biopharma will post 1.56 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the transaction, the senior vice president owned 213,476 shares in the company, valued at approximately $3,635,496.28. This trade represents a 5.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the business's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the transaction, the insider directly owned 9,174,453 shares of the company's stock, valued at $155,965,701. This trade represents a 0.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 350,011 shares of company stock worth $6,016,830. Company insiders own 7.65% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new stake in shares of Theravance Biopharma in the 1st quarter valued at approximately $2,076,000. Wedge Capital Management L L P NC acquired a new position in Theravance Biopharma during the 2nd quarter worth approximately $2,190,000. Precision Wealth Strategies LLC bought a new position in Theravance Biopharma in the 1st quarter valued at approximately $1,019,000. Dimensional Fund Advisors LP lifted its stake in Theravance Biopharma by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company's stock valued at $15,960,000 after purchasing an additional 124,658 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new stake in Theravance Biopharma in the first quarter valued at approximately $1,672,000. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company's work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.